Clinical trial

Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis

NCT01712945

Study summary

ClinicalTrials.gov

Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Palifermin Normalized identity: palifermin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Alemtuzumab Normalized identity: alemtuzumab View linked drug · Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2012-06-01

PhasePHASE1 / PHASE2

Conditions

Multiple Sclerosisverified · MONDO: multiple sclerosis

Interventions

PaliferminDRUG · verified · RxNorm: palifermin

AlemtuzumabDRUG · verified · RxNorm: alemtuzumab

Sponsors & collaborators

Cambridge University Hospitals NHS Foundation Trustlead sponsor

Mapped research locations

CambridgeCambridgeshire, United Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01712945 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.